Home / Resources / Videos / ADA 2018 / Sam Engel on CompoSIT and VERTIS Trials: DIC Interview

Sam Engel on CompoSIT and VERTIS Trials: DIC Interview




In this Exclusive Interview, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about diabetes drugs in the pipeline at Merck; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and the problem of “clinical inertia” in intensifying treatment.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. 

SamuelEngel2017Dr. Sam Engel is the Associate Vice President, Cardiometabolic and Women’s Health at Merck Research Laboratories. He graduated from New York University School of Medicine. Prior to joining Merck’s team, he was a Clinical Professor at Albert Einstein College of Medicine.

 

 

View Full Video InterviewRead Full Interview Transcript

Video Segments:

Pt.1:   CompoSIT-I Study                   

Pt.2: CompoSIT-R Study

Pt.3: Merck Diabetes Drugs Future and Present

Pt.4: The Ramifications of Clinical Inertia

Pt.5: CGM Effect on Diabetes

 

Full Video: